AGDS-CellO – Microbiome Study PICF

Thank you for your interest in participating in this project. We will now begin the formalities of actively recruiting you into the project by collecting your personal details and obtaining your formal consent. The instructions below will walk you through the process for this formal consent.

Instructions:

1. Click on the title of each section to read the information required to participate.
2. Sections that are marked with ✅ must be read and agreed to by clicking the checkbox at the bottom of each.
3. Click on "I Agree and Wish to proceed" at the bottom of the page to consent to participate.
*Note: You will not be able to provide your consent unless you indicate your agreement to the sections marked.


Participant Information Sheet and Consent Form


Title Investigating the Interaction Between Antidepressant Medication and the Gut Microbiome
Short Title AGDS-CellO - Microbiome
Coordinating Principal Investigator Professor Naomi Wray
Principal Investigator Dr. Amedeo MiniChino
Location The University of Queensland
University of Oxford


1. Introduction

You are invited to take part in a research study Investigating the interaction between antidepressant medication and the gut microbiome. This form provides detailed information about the study to help you decide whether or not to participate.

The human gut is home to trillions of microorganisms, collectively known as the gut microbiome, which play a vital role in digestion, immune function, and overall health. In recent years, emerging research has highlighted the gut-brain axis - a complex communication network between the gut and the brain - suggesting that gut microbiota can influence mood, cognition, and mental health.

Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), are commonly prescribed for depression and other mood disorders. While these medications primarily act on the brain's neurochemical pathways, evidence is growing that they may also impact the gut microbiome—potentially affecting treatment outcomes, side effects, and even individual responses to therapy.

However, current research on the interaction between antidepressants and the gut microbiome is limited and largely based on animal models or small-scale studies. Human-based data are urgently needed to understand how antidepressants may alter gut microbial composition and whether this plays a role in mental health outcomes or gastrointestinal side effects.

✅ If You Are Ready to Proceed

If you have read and fully understood the information above, and you are ready to move on to the next part of the consent process, please click the button below.

Version1.1_15 June 2026